Nayanta Sodha

Summary

Affiliation: Institute of Cancer Research
Country: UK

Publications

  1. ncbi request reprint Rare germ line CHEK2 variants identified in breast cancer families encode proteins that show impaired activation
    Nayanta Sodha
    Royal Marsden NHS Foundation Trust The Institute of Cancer Research, Sutton, Surrey, United Kingdom
    Cancer Res 66:8966-70. 2006
  2. ncbi request reprint A robust method for detecting CHK2/RAD53 mutations in genomic DNA
    Nayanta Sodha
    Royal Marsden NHS Trust, Surrey, UK
    Hum Mutat 19:173-7. 2002
  3. ncbi request reprint BRCA1/BRCA2 mutation status and analysis of cancer family history in participants of the Royal Marsden Hospital tamoxifen chemoprevention trial
    Zsofia Kote-Jarai
    Translational Cancer Genetics Team, Section of Cancer Genetics, The Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK
    Cancer Lett 247:259-65. 2007
  4. ncbi request reprint Analysis of familial male breast cancer for germline mutations in CHEK2
    Nayanta Sodha
    Royal Marsden NHS Trust, Downs Road, Sutton SM2 5PT, UK
    Cancer Lett 215:187-9. 2004
  5. ncbi request reprint CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin?
    Laurent Antoni
    Cancer Research UK Centre for Cancer Therapeutics, Institute of Cancer Research, Haddow Laboratories, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK
    Nat Rev Cancer 7:925-36. 2007
  6. pmc Overexpression of RAD51 occurs in aggressive prostatic cancer
    Anita Mitra
    Translational Cancer Genetics Team, Section of Cancer Genetics, The Institute of Cancer Research, Sutton, Surrey, UK
    Histopathology 55:696-704. 2009
  7. ncbi request reprint Increasing evidence that germline mutations in CHEK2 do not cause Li-Fraumeni syndrome
    Nayanta Sodha
    Hum Mutat 20:460-2. 2002
  8. ncbi request reprint Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations
    Hanne Meijers-Heijboer
    Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, The Netherlands
    Nat Genet 31:55-9. 2002
  9. pmc A multicenter study of cancer incidence in CHEK2 1100delC mutation carriers
    Deborah Thompson
    Genetic Epidemiology Unit, Strangeways Research Laboratories, University of Cambridge, Worts Causeway, Cambridge, CB1 8RN, United Kingdom
    Cancer Epidemiol Biomarkers Prev 15:2542-5. 2006
  10. ncbi request reprint Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype
    Magali Olivier
    IARC, Lyon, Cedex 8, France
    Cancer Res 63:6643-50. 2003

Collaborators

Detail Information

Publications10

  1. ncbi request reprint Rare germ line CHEK2 variants identified in breast cancer families encode proteins that show impaired activation
    Nayanta Sodha
    Royal Marsden NHS Foundation Trust The Institute of Cancer Research, Sutton, Surrey, United Kingdom
    Cancer Res 66:8966-70. 2006
    ..In addition, the results imply that these mutations, as well as 1100delC, cannot act in a dominant-negative manner to cause cancer, and tumorigenesis in association with these mutations may be due to haploinsufficiency...
  2. ncbi request reprint A robust method for detecting CHK2/RAD53 mutations in genomic DNA
    Nayanta Sodha
    Royal Marsden NHS Trust, Surrey, UK
    Hum Mutat 19:173-7. 2002
    ..To circumvent this problem, we have developed a strategy, based on long-range PCR, to screen the functional copy of CHK2. Using this approach it is possible to carry out a comprehensive mutational analysis of CHK2 from genomic DNA...
  3. ncbi request reprint BRCA1/BRCA2 mutation status and analysis of cancer family history in participants of the Royal Marsden Hospital tamoxifen chemoprevention trial
    Zsofia Kote-Jarai
    Translational Cancer Genetics Team, Section of Cancer Genetics, The Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK
    Cancer Lett 247:259-65. 2007
    ..03) in the cancers developing in tamoxifen-treated patients. These results suggest that tamoxifen is less likely to be effective at reducing breast cancers which are ER negative and also in some individuals at higher HR...
  4. ncbi request reprint Analysis of familial male breast cancer for germline mutations in CHEK2
    Nayanta Sodha
    Royal Marsden NHS Trust, Downs Road, Sutton SM2 5PT, UK
    Cancer Lett 215:187-9. 2004
    ..One individual was found to harbour the 1100delC variant. No other mutations were identified. Variants other than 1100delC are rare in male breast cancer...
  5. ncbi request reprint CHK2 kinase: cancer susceptibility and cancer therapy - two sides of the same coin?
    Laurent Antoni
    Cancer Research UK Centre for Cancer Therapeutics, Institute of Cancer Research, Haddow Laboratories, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK
    Nat Rev Cancer 7:925-36. 2007
    ....
  6. pmc Overexpression of RAD51 occurs in aggressive prostatic cancer
    Anita Mitra
    Translational Cancer Genetics Team, Section of Cancer Genetics, The Institute of Cancer Research, Sutton, Surrey, UK
    Histopathology 55:696-704. 2009
    ..To test the hypothesis that, in a matched series of prostatic cancers, either with or without BRCA1 or BRCA2 mutations, RAD51 protein expression is enhanced in association with BRCA mutation genotypes...
  7. ncbi request reprint Increasing evidence that germline mutations in CHEK2 do not cause Li-Fraumeni syndrome
    Nayanta Sodha
    Hum Mutat 20:460-2. 2002
  8. ncbi request reprint Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations
    Hanne Meijers-Heijboer
    Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, The Netherlands
    Nat Genet 31:55-9. 2002
    ....
  9. pmc A multicenter study of cancer incidence in CHEK2 1100delC mutation carriers
    Deborah Thompson
    Genetic Epidemiology Unit, Strangeways Research Laboratories, University of Cambridge, Worts Causeway, Cambridge, CB1 8RN, United Kingdom
    Cancer Epidemiol Biomarkers Prev 15:2542-5. 2006
    ..Our results suggest that the risk of cancer associated with CHEK2 1100delC mutations is restricted to breast cancer, although we cannot rule out a small increase in overall cancer risk...
  10. ncbi request reprint Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype
    Magali Olivier
    IARC, Lyon, Cedex 8, France
    Cancer Res 63:6643-50. 2003
    ..004). These observations have clinical implications for genetic testing and tumor surveillance in LFS/LFL families...